Diagnosis and Prognostication of Ductal Adenocarcinomas of the Pancreas Based on Genome-Wide DNA Methylation Profiling by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification by Gotoh, Masahiro et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 780836, 10 pages
doi:10.1155/2011/780836
Research Article
Diagnosis and Prognostication of Ductal Adenocarcinomas of
the Pancreas Based on Genome-WideDNA Methylation Proﬁling
byBacterialArtiﬁcial ChromosomeArray-Based Methylated CpG
Island Ampliﬁcation
Masahiro Gotoh,1 Eri Arai,1 Saori Wakai-Ushijima,1 Nobuyoshi Hiraoka,1 Tomoo Kosuge,2
Fumie Hosoda,3 TatsuhiroShibata,3 Tadashi Kondo,4 SanaYokoi,5,6 IsseiImoto,5
Johji Inazawa,5 andYaeKanai1
1Pathology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 104-0045, Japan
3Cancer Genomics Project, National Cancer Center Research Institute, Tokyo 104-0045, Japan
4Proteome Bioinformatics Project, National Cancer Center Research Institute, Tokyo 104-0045, Japan
5Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science,
Tokyo Medical and Dental University, Tokyo 113-8510, Japan
6Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
Correspondence should be addressed to Yae Kanai, ykanai@ncc.go.jp
Received 22 July 2010; Accepted 12 November 2010
Academic Editor: Alain Filloux
Copyright © 2011 Masahiro Gotoh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
To establish diagnostic criteria for ductal adenocarcinomas of the pancreas (PCs), bacterial artiﬁcial chromosome (BAC) array-
based methylated CpG island ampliﬁcation was performed using 139 tissue samples. Twelve BAC clones, for which DNA
methylation status was able to discriminate cancerous tissue (T) from noncancerous pancreatic tissue in the learning cohort with
a speciﬁcity of 100%, were identiﬁed. Using criteria that combined the 12 BAC clones, T-samples were diagnosed as cancers
with 100% sensitivity and speciﬁcity in both the learning and validation cohorts. DNA methylation status on 11 of the BAC
clones, which was able to discriminate patients showing early relapse from those with no relapse in the learning cohort with 100%
speciﬁcity, was correlated with the recurrence-free and overall survival rates in the validation cohort and was an independent
prognostic factor by multivariate analysis. Genome-wide DNA methylation proﬁling may provide optimal diagnostic markers and
prognostic indicators for patients with PCs.
1.Introduction
It is known that DNA hypomethylation results in chro-
mosomal instability as a result of changes in chromatin
structure and that DNA hypermethylation of CpG islands
silences tumor-related genes in cooperation with histone
modiﬁcation in human cancers [1–5]. The incidence of
DNA methylation alterations is generally high in cancers of
various organs, and particular DNA methylation proﬁles are
signiﬁcantly associated with poorer tumor diﬀerentiation,
tumor aggressiveness, and poor prognosis [6–8]. Moreover,
unlike alterations of mRNA and protein expression, which
can be easily aﬀected by the microenvironment of cancer
cells, DNA methylation alterations are stably preserved on
DNA double strands by covalent bonds and can be detected
using highly sensitive methodology. Therefore, alterations of
DNAmethylationcanbecomeoptimal diagnostic markersof
cancers and prognostic indicators for aﬀected patients.
With regard to pancreatic carcinogenesis, we have
reported that accumulation of DNA methylation of tumor-
related genes [9] is associated with overexpression of DNA
methyltransferase (DNMT) 1 [10], the major DNMT, even2 Journal of Biomedicine and Biotechnology
in peripheral pancreatic duct epithelia with an inﬂammatory
background, in comparison with normal peripheral pancre-
atic duct epithelia. Ductal adenocarcinomas of the pancreas
frequently develop after chronic damage due to pancreatitis,
and at least a proportion of peripheral pancreatic duct
epithelia with an inﬂammatory background are at the
precancerous stage [11]. The average number of methy-
lated tumor-related genes and the incidence of DNMT1
overexpression increase progressively with the progression
of another precancerous lesion, pancreatic intraductal neo-
plasia [12], to well-diﬀerentiated ductal adenocarcinoma,
and ﬁnally to poorly diﬀerentiated ductal adenocarcinoma,
suggesting that DNA methylation alterations participate in
multistage pancreatic carcinogenesis [9, 10]. However, even
though we and other groups have examined the DNA
methylation status of several speciﬁc tumor-related genes
[9, 13–17], only a few previous studies have employed
recently developed array-based technology for analysis of
DNAmethylationinductaladenocarcinomasofthepancreas
[18, 19]. To our knowledge, no diagnostic criteria have yet
been established for pancreatic cancers on the basis of such
genome-wide DNA methylation proﬁling.
In the present study, in order to obtain diagnostic mark-
ers and prognostic indicators of ductal adenocarcinomas of
the pancreas, we performed bacterial artiﬁcial chromosome
(BAC) array-based methylated CpG island ampliﬁcation
(BAMCA) [20–22], which is a technique suitable for
overviewing the DNA methylation tendency of individual
large regions among all chromosomes [23, 24], in samples
of normal pancreatic tissue obtained from patients without
ductal adenocarcinomas (C), noncancerous pancreatic tissue
obtained from patients with ductal adenocarcinomas (N),
and cancerous tissue (T).
2.MaterialsandMethods
2.1. Patients and Tissue Samples. Ninety-one T-samples were
obtained from surgically resected specimens from patients
with ductal adenocarcinomas who underwent pancreatec-
tomy at the National Cancer Center Hospital, Tokyo, Japan,
between 2003 and 2008. From 33 of the 91 patients, N-
samples were also obtained from the same surgically resected
specimens. Microscopic examination of the histological
specimens taken from a region immediately adjoining that
from which N-samples had been obtained revealed various
degrees of chronic pancreatitis, but no contaminating cancer
cells. Fifteen C-samples were obtained from patients without
ductal adenocarcinomas who underwent pancreatectomy for
metastasis of renal cell carcinoma (1 patient), adenocarci-
noma of the gallbladder (3 patients), adenocarcinoma of the
papilla of Vater (6 patients), serous cystadenoma (1 patient),
mucinous cystadenoma (1 patient), solid-pseudopapillary
neoplasm (1 patient), endocrine tumor (1 patient) of the
pancreas, and lymphoplasmacytic pancreatitis (1 patient).
The total samples were randomly divided into a learning
cohort (8 C-, 17 N-, and 46 T-samples) and a validation
cohort (7 C-, 16 N-, and 45 T-samples). In the learning
cohort, patients from whom C-, N-, and T-samples were
obtained comprised 5 men and 3 women with a mean
age of 69.6 ± 8.1( m e a n± SD) years, 6 men and 11
women with a mean age of 67.6 ± 10.1y e a r s ,a n d2 8
men and 18 women with a mean age of 64.2 ± 10.8
years,respectively.Inthevalidationcohort,thepatientsfrom
whom C-, N-, and T-samples were obtained comprised 3
m e na n d4w o m e nw i t ham e a na g eo f6 2 .9 ± 18.2y e a r s ,
11 men and 5 women with a mean age of 65.0 ± 8.7y e a r s ,
and 27 men and 18 women with a mean age of 64.6 ±
9.7 years, respectively. The clinicopathological parameters of
patients who provided T-samples in both the learning and
validation cohorts are summarized in Table 1. This study was
approved by the Ethics Committee of the National Cancer
Center, Tokyo, Japan, and was performed in accordance with
the Declaration of Helsinki, 1995. All patients gave their
informed consent prior to their inclusion in this study.
2.2. BAMCA. High-molecular-weight DNA from fresh
frozen tissue samples was extracted using phenol-
chloroform, followed by dialysis. DNA methylation status
was analyzed by BAMCA using a custom-made array (MCG
Whole Genome Array-4500) harboring 4361 BAC clones
located throughout chromosomes 1 to 22, X and Y [25],
as described previously [23, 26, 27]. Brieﬂy, a mixture of
normal pancreatic tissue DNA obtained from 8 C-samples
in the learning cohort was used as a reference for all analyses
of test DNA samples in both the learning and validation
cohorts. Five-microgram aliquots of test or reference
DNA were ﬁrst digested with 100 units of methylation-
sensitive restriction enzyme Sma I( N E B ,I p s w i c h ,M A )a n d
subsequently with 20 units of methylation-insensitive Xma
I (NEB). Adapters were ligated to Xma I-digested sticky
ends, and polymerase chain reaction (PCR) was performed
with an adapter primer set. Test and reference PCR products
were labeled by random priming with Cy3- and Cy5-dCTP
(GE Healthcare, Buckinghamshire, UK), respectively, and
precipitated together with ethanol in the presence of Cot-I
DNA (Invitrogen, Carlsbad, CA). The mixture was applied
to array slides and incubated at 43
◦Cf o r6 3h .A r r a y sw e r e
scanned with a GenePix Personal 4100A (Molecular Devices,
Sunnyvale, CA) and analyzed using GenePix Pro 5.0 imaging
software (Molecular Devices) and Acue 2 software (Mitsui
Knowledge Industry, Tokyo, Japan). The signal ratios were
normalized in each sample to make the mean signal ratios of
all BAC clones 1.0. The reproducibility of BAMCA data was
conﬁrmed in representative samples by the duplicate study
(data not shown).
2.3. Statistics. BAC clones whose signal ratios obtained by
BAMCA diﬀered signiﬁcantly between the groups of samples
were identiﬁed by Wilcoxon test. Survival curves of patient
groups were calculated by the Kaplan-Meier method, and
the diﬀerences were compared using the Log-rank test. The
Cox proportional hazards multivariate model was used to
examine the prognostic impact of DNA methylation status,
surgical margin status (R0 versus R1 or R2) [28]a n dl y m p h
node metastasis. Diﬀerences at P <. 05 were considered
signiﬁcant.Journal of Biomedicine and Biotechnology 3
T N C
(a)
ID of BAC clone ID of BAC clone ID of BAC clone
CNT
1.5
0.67
0 1000 2000 3000 4000
10
1
0.1
S
i
g
n
a
l
r
a
t
i
o
(
t
e
s
t
/
r
e
f
r
e
n
c
e
)
0 1000 2000 3000 4000
10
1
0.1
0 1000 2000 3000 4000
10
1
0.1
(b)
Figure 1: Genome-wide DNA methylation analysis by BAMCA. (a) Representative examples of scanned array images in a sample of normal
pancreatic tissue obtained from a patient without ductal adenocarcinoma of the pancreas (C) and samples of both noncancerous pancreatic
tissue (N) and cancerous tissue (T) obtained from a single patient with ductal adenocarcinoma of the pancreas. Test and reference DNA
labeled with Cy3 and Cy5 was cohybridized, respectively. (b) Representative examples of scattergrams of the signal ratios (test signal/
reference signal) in each C-, N-, and T-sample. In all C-samples, the signal ratios of 97% of the BAC clones were between 0.67 and 1.5
(red lines). Therefore, in N- and T samples, DNA methylation status corresponding to a signal ratio of less than 0.67 and more than 1.5 was
deﬁned as DNA hypo- and hypermethylation on each BAC clone relative to C-samples, respectively. In N-samples, many BAC clones showed
DNA hypo- or hypermethylation. In T-samples, more BAC clones showed DNA hypo- or hypermethylation, and the degree of DNA hypo-
or hypermethylation, that is, deviation of the signal ratio from 0.67 or 1.5, was increased in comparison with N-samples.
3. Results
3.1. Genome-Wide DNA Methylation Alterations in Tissue
Samples. Figure 1 shows representative examples of scanned
array images and scattergrams of the signal ratios (test
signal/ reference signal) for a C-sample, a N-sample, and the
corresponding T-sample. In all C-samples, the signal ratios
of 97% of the BAC clones were between 0.67 and 1.5 (red
lines in Figure 1(b)). Therefore, in N- and T-samples, DNA
methylation status corresponding to a signal ratio of less
than 0.67 and more than 1.5 was deﬁned as DNA hypo-
and hypermethylation of each BAC clone relative to C-
samples, respectively, as in our previous studies [23, 26, 27].
In N-samples, many BAC clones showed DNA hypo- or
hypermethylation (Figure 1(b)). In T-samples, more BAC
clones showed DNA hypo- or hypermethylation, and the
degree of DNA hypo- or hypermethylation, that is, deviation
of the signal ratio from 0.67 or 1.5, was increased in
comparison with N-samples (Figure 1(b)).
3.2. Establishment of Criteria for Diagnosis of Ductal Adeno-
carcinomas of the Pancreas Based on DNA Methylation Pro-
ﬁles. Wilcoxon test (P <. 01) revealed that the average signal
ratiosof331BACclones(SupplementaryTableSIavailableat
doi:10.1155/2011/780836) inT-samplesdiﬀeredsigniﬁcantly
from those in both C- and N-samples. Figure 2(a) shows
scattergrams of the signal ratios for representative examples
of the 331 BAC clones: RP11-88P10 and RP11-424K7
were able to discriminate T-samples from both C- and N-
samples with 100% speciﬁcity (the ratio of the number of
true negatives to the number of true negatives and false4 Journal of Biomedicine and Biotechnology
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Figure 2: Establishment of criteria for diagnosis of ductal adenocarcinomas of the pancreas. (a) Scattergrams of the signal ratios in samples
of normal pancreatic tissue obtained from patients without ductal adenocarcinomas (C), noncancerous pancreatic tissue obtained from
patients with ductal adenocarcinomas (N) and cancerous tissue (T) on representative BAC clones, RP11-88P10 and RP11-424K7. Using the
cutoﬀ values indicated by the dotted lines, T-samples were discriminated from both C- and N-samples in the learning cohort with 100%
speciﬁcity. (b) Histogram showing the number of BAC clones satisfying the criteria listed in Table 2 in the learning cohort (n = 71). C-, N-
andT-samplesareindicatedbyempty,shaded,andﬁlledcolumns,respectively.Basedonthishistogram,weestablishedthefollowingcriteria:
when the tissue samples satisﬁed the criteria listed in Table 2 for 1 or more BAC clones (dotted line), they were judged to be cancerous tissue,
and when tissue samples did not satisfy the criteria for any BAC clone, they were judged not to be cancerous tissue. Based on these criteria,
both the sensitivity and speciﬁcity for diagnosis of T-samples in the learning cohort as being cancerous were 100%. (c) Validation of the
above criteria using 68 additional tissue samples in the validation cohort. All 45 validation samples satisfying the criteria in Table 2 for 1 or
more BAC clones (dotted line) were T-samples (ﬁlled columns), and all 23 validation samples not satisfying the criteria in Table 2 for any
BAC clone were C- (empty column) or N- (shaded column) samples. Both the sensitivity and speciﬁcity for diagnosis of T-samples in the
validation cohort as being cancerous were again 100%.
positives) using cutoﬀ values of 0.86 and 1.29 (dotted lines
in Figure 2(a)), respectively, (speciﬁcity was calculated as the
ratio of the number of C- and N-samples showing signal
ratios of 0.86 or more than 0.86 and 1.29 or less than 1.29
relative to the total number of C- and N-samples, resp.).
The cutoﬀ values of the signal ratios and sensitivities (the
ratios of the number of true positives to the number of true
positives and false negatives) of 12 BAC clones for which
such discrimination was performed with 100% speciﬁcity
are shown in Table 2. Genes located on the 12 BAC clonesJournal of Biomedicine and Biotechnology 5
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Figure 3: Establishment of criteria for prognostication of patients with ductal adenocarcinomas of the pancreas. (a) Scattergrams of the
signal ratios in samples of cancerous tissue obtained from patients in the no-relapse group (NR, n = 4) and early-relapse group (ER,
n = 17) who had not undergone adjuvant chemotherapy with gemcitabine after surgery on representative bacterial artiﬁcial chromosome
(BAC) clones, RP11-165B11 and RP11-92A14. Using the cutoﬀ values indicated by the dotted lines, patients belonging to the ER-group were
discriminated from those belonging to the NR-group in the learning cohort with 100% speciﬁcity. (b) Histogram showing the number of
BAC clones satisfying the criteria listed in Table 3 for patients belonging to the NR- (shaded column) and ER- (ﬁlled columns) groups in
the learning cohort. (c) Kaplan-Meier survival curves of 34 patients who had not undergone adjuvant chemotherapy with gemcitabine after
surgery in the validation cohort. Both the recurrence-free and overall survival rates of 29 patients satisfying the criteria listed in Table 3 for
2 or more BAC clones (solid lines) were signiﬁcantly lower than those of 5 patients satisfying the criteria listed in Table 3 for less than 2 BAC
clones (dotted lines). Log-rank test (P = .0044 and P = .014, resp.).6 Journal of Biomedicine and Biotechnology
Table 1: Clinicopathological parameters of patients with ductal
adenocarcinomas of the pancreas.
Clinicopathological
parameters
Number of patients
Learning cohort Validation cohort
Greatest diameter of the
tumor
2.0cm or less 21
More than 2.0cm, but
no more than 4.0cm
29 29
More than 4.0cm 15 15
Histological classiﬁcation
Well diﬀerentiated
adenocarcinoma
24
Moderately
diﬀerentiated
adenocarcinoma
35 30
Poorly diﬀerentiated
adenocarcinoma
69
Adenosquamous
carcinoma
21
Mucinous noncystic
carcinoma
11
Lymphatic vessel invasion
Negative 00
Positive 46 45
Venous invasion
Negative 00
Positive 46 45
Lymph node metastasis
Negative 13 9
Positive 33 36
Status of the surgical
margin
Negative (R0
∗) 27 33
Positive (R1 or R2
∗) 19 12
Total 46 45
∗deﬁned in [28].
are summarized in Supplementary Table SII. A histogram
showing the number of BAC clones satisfying the criteria
listed in Table 2 in 8 C-samples, 17 N-samples, and 46 T-
samples in the learning cohort is shown in Figure 2(b).
Based on this histogram, we ﬁnally established the following
criteria: when tissue samples satisﬁed the criteria in Table 2
for 1 or more BAC clones, they were judged to be ductal
adenocarcinomas, and when tissue samples did not satisfy
the criteria for any BAC clone, they were judged not to
be ductal adenocarcinomas. Based on these criteria, both
the sensitivity and speciﬁcity for diagnosis of T-samples in
the learning cohort as ductal adenocarcinomas were 100%
(sensitivity was calculated as the ratio of the number of T-
samples satisfying the criteria in Table 2 for 1 or more BAC
clones to the total number of T-samples, and speciﬁcity was
calculated as the ratio of the number of C- and N-samples
notsatisfyingthecriteriainTable 2 foranyBACclonerelative
to the total number of C- and N-samples).
To conﬁrm these criteria, 68 additional tissue samples
in the validation cohort were analyzed. Forty-ﬁve samples
satisfying the criteria listed in Table 2 for 1 or more BAC
clones were all T-samples, and the other 23 samples not
satisfying the criteria listed in Table 2 for any BAC clone
were all C- or N-samples (Figure 2(c)). Our criteria enabled
diagnosis of T-samples in the validation cohort as ductal
adenocarcinomas with 100% sensitivity and speciﬁcity.
3.3. Establishment of Criteria for Prognostication of Patients
with Ductal Adenocarcinomas of the Pancreas Based on
DNA Methylation Proﬁles. To establish criteria for prog-
nostication, 21 patients who had not undergone adjuvant
chemotherapy with gemcitabine in the learning cohort were
divided into two groups: 4 patients who had not suﬀered
relapse for more than 4 years after pancreatectomy and 17
patients who had suﬀered relapse within 18 months after
pancreatectomy were deﬁned as the no-relapse group and
early-relapse group, respectively. The period covered ranged
from 215 to 1,846 days (mean, 823 days). Wilcoxon test (P
<. 05)revealedthattheaveragesignalratiosof64BACclones
diﬀered signiﬁcantly between T-samples obtained from the
no-relapse group and those from the early-relapse group.
Figure 3(a) shows scattergrams of the signal ratios for
representative examples of the 64 BAC clones: RP11-165B11
and RP11-92A14 were able to discriminate T-samples from
patients belonging to the early-relapse group from those
belonging to the no-relapse group with 100% speciﬁcity (the
ratio of the number of true negatives to the number of true
negatives and false positives) using cutoﬀ values of 1.29 and
1.03 (dotted lines in Figure 3(a)), respectively, (speciﬁcity
was calculated as the ratio of the number of T-samples
from patients belonging to the no-relapse group showing
signal ratios of 1.29 or more than 1.29 and 1.03 or less than
1.03 relative to the total number of T-samples from patients
belonging to the no-relapse group, resp.). The cutoﬀ values
of the signal ratios and sensitivities (the ratios of the number
of true positives to the number of true positives and false
negatives) of 11 BAC clones for which such discrimination
was performed with 100% speciﬁcity are shown in Table 3.
Genes located on the 11 BAC clones are summarized in
Supplementary Table SII. A histogram showing the number
of BAC clones satisfying the criteria listed in Table 3 in
4 T-samples from the no-relapse group and 17 T-samples
from the early-relapse group in the learning cohort is shown
in Figure 3(b). Based on these criteria (2 or more BAC
clones versus less than 2 BAC clones listed in Table 3), both
the sensitivity and speciﬁcity of discrimination of patients
belonging to the early-relapse group from those belonging
to the no-relapse group in the learning cohort were 100%
(sensitivity was calculated as the ratio of the number of T-
samples from patients belonging to the early-relapse group
satisfying the criteria in Table 3 for 2 or more BAC clones
relative to the total number of T-samples from patients
belonging to the early-relapse group, and speciﬁcity was
calculated as the ratio of the number of T-samples fromJournal of Biomedicine and Biotechnology 7
Table 2: Twelve BAC clones that were able to discriminate samples of cancerous tissue from samples of normal pancreatic tissue
obtained from patients without ductal adenocarcinomas and samples of noncancerous pancreatic tissue obtained from patients with ductal
adenocarcinomas in the learning cohort with 100% speciﬁcity.
BAC clone ID Location Cutoﬀ value (CV) DNA methylation status∗ Sensitivity (%) Speciﬁcity (%)
RP11-121D3 3p26.3 1.46 CV< 43.5 100
RP11-89G4 5q31.1 0.80 CV> 37.0 100
RP11-177M14 6q23.2 1.45 CV< 67.4 100
RP11-92I18 10q11.23 1.34 CV< 67.4 100
RP11-36H11 11p13-11p12 0.56 CV> 26.7 100
RP11-91M21 12q24.21 1.49 CV< 53.3 100
RP11-458A21 14q13.3 1.29 CV< 72.7 100
RP11-88P10 15q12 0.86 CV> 53.3 100
RP11-424K7 16q12.1 1.29 CV< 75.0 100
RP11-2O22 19q13.31 1.16 CV< 33.3 100
RP11-149O7 20p12.3 1.22 CV< 31.1 100
RP11-79G10 20q12 1.16 CV< 35.6 100
∗CV>, when the signal ratio was lower than the cutoﬀ value, the tissue sample was considered to be cancerous; CV <, when the signal ratio was higher than
the cutoﬀ value, the tissue sample was considered to be cancerous.
Table 3: Eleven BAC clones that were able to discriminate patients belonging to the early-relapse group from those belonging to the no-
relapse group in the learning cohort with 100% speciﬁcity.
BAC clone ID∗ Location Cutoﬀ value (CV) DNA methylation status∗∗ Sensitivity (%) Speciﬁcity (%)
RP11-101J8 1q23.1 0.98 CV< 47.1 100
RP11-137N24 1q25.1 1.08 CV< 58.8 100
RP11-180L21 2p21 0.97 CV< 37.5 100
RP11-91K8 3q22.1 0.84 CV< 41.2 100
RP11-89E2 4q28.2 0.99 CV< 58.8 100
RP11-81B23 5p14.3 0.99 CV> 50.0 100
RP11-373P23 10q21.1 1.04 CV< 29.4 100
RP11-666F17 12p11.23 1.15 CV> 58.8 100
RP11-165B11 16p13.13 1.29 CV> 76.5 100
RP11-236B14 19q13.33 0.87 CV> 52.9 100
RP11-92A14 21q21.1 1.03 CV< 53.3 100
∗CV>, when the signal ratio was lower than the cutoﬀ value, the sample of cancerous tissue was considered to originate from a patient who would suﬀer early
relapse; CV<, when the signal ratio was higher than the cutoﬀ value, the sample of cancerous tissue was considered to originate from a patient who would
suﬀer early relapse.
Table 4: Multivariate analysis of clinicopathological parameters and DNA methylation proﬁles associated with recurrence-free and overall
survival in patients with ductal adenocarcinomas of the pancreas.
Recurrence-free survival Overall survival
Parameters Hazard ratio (95% CI∗) χ2 P Hazard ratio (95% CI) χ2 P
Status of the surgical margin
Negative (R0∗∗, n = 60) 1 1
Positive (R1 or R2 ∗∗, n = 31) 1.072 (0.645–1.782) 0.071 .7898 1.452 (0.804–2.619) 1.531 .2159
Lymph node metastasis
Negative (n = 22) 1 1
Positive (n = 69) 1.621 (0.878–2.995) 2.383 .1227 1.477 (0.709–3.073) 1.086 .2973
The criteria in Table 3
Satisfying for less than 2 BAC clones (n = 10) 1 1
Satisfying for 2 or more BAC clones (n = 81) 18.694 (2.559–136.555) 8.331 .0039 12.136 (1.660–88.711) 6.051 .0139
∗ CI, conﬁdence interval; ∗∗ deﬁned in [28].8 Journal of Biomedicine and Biotechnology
patients belonging to the no-relapse group satisfying the
criteria in Table 3 for less than 2 BAC clones relative to the
total number of T-samples from patients belonging to the
no-relapse group).
To conﬁrm these criteria, 34 additional T-samples
obtained from patients who had not undergone adjuvant
chemotherapy with gemcitabine after surgery in the valida-
tion cohort were analyzed. The period covered ranged from
92 to 2,274 days (mean, 612 days). Both the recurrence-free
and overall survival rates of 29 patients satisfying the criteria
listed in Table 3 for 2 or more BAC clones were signiﬁcantly
lower than those of 5 patients satisfying the criteria listed in
Table 3 for less than 2 BAC clones (Figure 3(c), P = .0044
and P = .014, resp.).
Moreover, multivariate analysis in all 91 patients with
ductal adenocarcinomas revealed that satisfying the criteria
listed in Table 3 for 2 or more BAC clones was a prognostic
parameter for both recurrence-free and overall survival that
was independent of surgical margin positivity (R1 or R2)
[28] and lymph node metastasis at the time of surgery, which
are known to have a prognostic impact [29–33]( Table 4).
4. Discussion
Ductal adenocarcinoma of the pancreas, one of the most
lethalofallhumancancers,isnowacommoncauseofcancer
mortality in the United States and Japan [34]. Due to its
aggressive growth behavior with early local spread into the
surrounding tissues mostly along neural sheaths, peritoneal
dissemination, and liver and lymph node metastasis, the
prognosis remains poor. Surgical treatment still provides
the only possibility of cure [35]. Although advances in
preoperative diagnostic imaging have made it possible to
detect tumors at an early stage when they are still resectable,
diagnosis using pancreatic biopsy and/or specimens of
pancreatic juice is indispensable before surgery. In general,
pancreatic biopsy yields only a small amount of tissue, and
in pancreatic juice specimens, the cellular morphology is
notwellpreservedduetodegeneration.Therefore,molecular
diagnosis is advantageous for supporting the histological
and/or cytological assessment of such specimens. DNA
methylation proﬁles, which are stably preserved on DNA
double strands by covalent bonds, even after degeneration
of cellular morphology, may become diagnostic markers in
pancreatic biopsy and/or pancreatic juice specimens.
We have previously established diagnostic criteria for
cancers of the kidney [26], liver [27] and urinary tract
[23] based on genome-wide DNA methylation proﬁles using
the BAC array-based approach, BAMCA, which can assess
DNA methylation status not only on promoter regions of
speciﬁc tumor-related genes but also on genomic regions in
which DNA hypomethylation aﬀects chromosomal instabil-
ity. Moreover, during human carcinogenesis, DNA methy-
lation status is frequently altered in a coordinated manner,
through processes such as long-range epigenetic silencing
[36], in large chromosome regions. Since BAMCA is suitable
foroverviewingtheDNAmethylationtendencyofindividual
large regions among all chromosomes [23, 24], we again
employed this method to establish diagnostic criteria for
ductal adenocarcinomas of the pancreas.
The results of BAMCA for C-samples reﬂected the DNA
methylation proﬁles of normal peripheral pancreatic duct
epithelia (the origin of ductal adenocarcinomas), acinar cells
and islet cells. In N-samples, BAMCA revealed DNA hypo-
or hypermethylation on many BAC clones in comparison
to C-samples (Figure 1(b)). Microscopic observation of N-
samplesrevealedlymphocytesandﬁbroblastsassociatedwith
various degrees of chronic pancreatitis, which is considered
to be one of the precancerous conditions for ductal aden-
carcinomas[11].Ourpreviousstudiesusingmicrodissection
and immunohistochemistry revealed accumulation of DNA
hypermethylation of tumor-related genes associated with
DNMT1 overexpression, even in peripheral pancreatic duct
epithelia at the precancerous stage [9, 10]. Therefore, the
results of BAMCA for N-samples may reﬂect the DNA
methylation proﬁles of peripheral pancreatic duct epithelia
at the precancerous stage, lymphocytes, ﬁbroblasts, acinar
cells, and islet cells. In order to diagnose ductal adenocarci-
nomas in tissue samples, cancer-speciﬁc DNA methylation
proﬁles should be discriminated from those of normal or
precancerous peripheral pancreatic duct epithelia, lympho-
cytes, ﬁbroblasts, acinar cells, and islet cells. Therefore, we
identiﬁed 12 BAC clones whose DNA methylation status was
able to discriminate T-samples from both C- and N-samples.
In both the learning and validation cohorts, the criteria
combining the 12 BAC clones were able to diagnose T-
samples as ductal adenocarcinomas with a sensitivity and
speciﬁcity of 100%. Our criteria may be advantageous
for supporting the histological diagnosis of tiny tissue
samples obtained by pancreatic biopsy. Discrimination of
cancer cells from exfoliated noncancerous epithelial cells and
lymphocytes using the 12 BAC clones may be applicable for
diagnosis using specimens of pancreatic juice. Development
of methodology for assessing DNA methylation status on
the 12 BAC clones in fewer cells may be more advantageous
for clinical application, as we have already established a
methodology for quantiﬁcation of DNA methylation levels
on speciﬁc CpG sites in a very small quantity of genomic
DNA for estimation of carcinogenetic risk in patients with
chronic liver diseases (unpublished data). Development of
this methodology means that if DNA methylation alterations
on the 12 BAC clones are not observed in circulating blood
cells, our criteria may become applicable for noninvasive
diagnosis of pancreatic cancers based on serum markers
that diﬀer from the widely used carbohydrate antigen 19-9,
whose serum levels are also elevated in patients with chronic
pancreatitis [37].
Even when resection with curative intent is performed
for patients with pancreatic cancers, the rate of disease
recurrence is high and the survival rate after surgery is poor.
As surgical resection alone has limitations, development
of nonsurgical treatments, including adjuvant therapy, is
needed in order to improve the prognosis of patients
with pancreatic cancers. Although previous studies have
suggested the eﬃcacy of adjuvant chemotherapy [38], it
should be carried out carefully, paying close attention to
adversereactions[39].InordertohelpdecidetheindicationsJournal of Biomedicine and Biotechnology 9
for such adjuvant chemotherapy after surgery, prognostic
indicators should be explored. The criteria listed in Table 3
were able to discriminate the early-relapse group from the
no-relapse group with 100% sensitivity and speciﬁcity in
the learning cohort. Signiﬁcant correlation between DNA
methylation status on the 11 BAC clones and the recurrence-
free and overall survival rates of patients with ductal
adenocarcinomas in the validation cohort validated the
criteria. Multivariate analysis revealed that our criteria were
able to predict recurrence-free and overall patient outcome
independently of parameters that had been reported to be
signiﬁcantly prognostic in many previous studies, such as
surgical margin positivity (R1 or R2) [28]a n dl y m p hn o d e
metastasis. Therefore, prognostication based on our criteria
may be promising for supportive use during followup after
surgical resection in patients with ductal adenocarcinomas
of the pancreas. Since histological heterogeneity is frequently
observed even in a ductal adenocarcinoma of the pancreas
from a single patient, the consistency of BAMCA data for
multiple T-samples obtained from a single tumor should be
carefully conﬁrmed in a prospective validation study before
clinical application of the prognostic criteria.
5. Conclusions
BAMCA revealed genome-wide DNA methylation alter-
ations in ductal adenocarcinomas of the pancreas. Criteria
combining the DNA methylation status on 12 BAC clones
were able to discriminate T-samples from both C- and N-
samples and to diagnose T-samples as ductal adenocarci-
nomas, with 100% sensitivity and speciﬁcity in both the
learning and validation cohorts. Satisfying the criteria using
11 BAC clones was able to predict the recurrence-free and
overall survival of patients with ductal adenocarcinomas
independently of surgical margin positivity (R1 or R2) [28]
and lymph node metastasis. Genome-wide DNA methyla-
tion proﬁling may provide optimal diagnostic markers for
pancreatic cancers and prognostic indicators for aﬀected
patients.
Abbreviation
BAC: Bacterial artiﬁcial chromosome
BAMCA: BAC array-based methylated CpG
island ampliﬁcation
DNMT: DNA methyltransferase.
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